Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

Lancet

Volumn 349, Issue 9044, 1997, Pages 20-22

  Bartholomew, Maria M ^a   Jansen, Robert W ^b   Jeffers, Lennox J ^a   Reddy, K Rajender ^a   Johnson, Lance C ^b   Bunzendahl, Hartwig ^c   Condreay, Lynn D ^b   Tzakis, Andreas G ^a   Schiff, Eugene R ^a   Brown, Nathaniel A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CULTURE; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; POINT MUTATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENT INFECTION; STRUCTURAL GENE;

EID: 0031037065     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02266-0     Document Type: Article

References (17)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
2. Van Thiel DH, Wright HI, Fagiuoli S. Liver transplantation for hepatitis B virus-associated cirrhosis: a progress report. Hepatology 1994; 20: 20S-23S.
3. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-47.
4. Davies SE, Portmann B, O'Grady JG, et al. Hepatic histology following transplantation for chronic hepatitis B virus infection including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-57.
5. Doong SL, Tsai CH, Schinazi RF, Liotta DC , Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-99.
6. Tyrrell DLJ, Fischer K, Sayani K. Treatment of chimpanzees and ducks with lamivudine 2′,3′-dideoxy-3′-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera. Clin Invest Med 1993; 16 (suppl 4): B77 (abstr).
7. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61.
8. Schinazi RF, Lloyd RM, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875-81.
9. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171: 1411-19.
10. Kaneko S, Miller RH, Fienstone SM, et al. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 1989; 86: 312-16.
11. Jansen RW, Johnson LC, Averett DR. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1993; 37: 441-47.
12. Condreay LD, Condreay JP, Jansen RW, Paff MT, Averett DR. (-)-cis-5-fluoro-1-[2-hydroxymethyl-1,3-oxathiolan-5-y1] cytosine [524w91] inhibits HBV replication in primary human hepatocytes. Antimicrob Agents Chemother 1996; 40: 520-23.
13. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 5653-56.
14. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxylmethyl)-1,3-oxanthiolan-5-y1]cytosine. Antimicrob Agents Chemother 1992; 36: 2686-92.
15. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-15.
16. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-13.
17. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.